PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist developed for laboratory and preclinical research. It has been investigated for its interaction with melanocortin receptors and the associated signaling pathways within the central nervous system. Ongoing experimental research continues to examine its pharmacological properties, receptor selectivity, and biological activity in controlled laboratory settings.

Key Research Areas:

• Melanocortin receptor pharmacology

• Neuropeptide signaling

• Central nervous system biology

• Receptor-mediated cellular signaling

• Neuroendocrine research

• Molecular and physiological signaling pathways

This product requires reconstitution.